Skip to main content
Erschienen in: Current Hypertension Reports 11/2018

01.11.2018 | Hypertension and the Kidney (RM Carey, Section Editor)

Catheter-Based Renal Denervation for Hypertension

verfasst von: Raymond R. Townsend, Paul A. Sobotka

Erschienen in: Current Hypertension Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review was undertaken to update readers on the field of therapeutic renal denervation for hypertension during the 2016 through 2018 period.

Recent Findings

After the failure of Symplicity HTN-3 to meet its top line objective, intense scrutiny revealed several possible concerns addressed by the newer investigations into the area of renal denervation. These included better device technology, more intense subject monitoring for off-protocol antihypertensive drug usage, and deeper penetration into the renal vasculature by the interventionist.

Summary

Whether untreated by medication for hypertension or on antihypertensive medication, renal denervation shows a clear, though moderate, blood pressure reduction. The failure of roughly one out of three patients with hypertension to respond to denervation procedures argues that there is room for improvement in choosing the optimal patient for this approach to hypertension management.
Literatur
1.
Zurück zum Zitat •• Krum H, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. First human series of patients treated for drug resistant hypertension using radiofrequency renal ablation. CrossRefPubMed •• Krum H, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. First human series of patients treated for drug resistant hypertension using radiofrequency renal ablation. CrossRefPubMed
2.
Zurück zum Zitat Esler MD, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.CrossRefPubMed Esler MD, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.CrossRefPubMed
3.
Zurück zum Zitat Kandzari DE, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. ClinCardiol. 2012;35(9):528–35. Kandzari DE, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. ClinCardiol. 2012;35(9):528–35.
4.
Zurück zum Zitat Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.CrossRefPubMed Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.CrossRefPubMed
5.
Zurück zum Zitat Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–7.CrossRefPubMed Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–7.CrossRefPubMed
6.
Zurück zum Zitat Kandzari DE, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. In: Eur.Heart J, vol. 36; 2014. p. 219–27. Kandzari DE, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. In: Eur.Heart J, vol. 36; 2014. p. 219–27.
7.
Zurück zum Zitat Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70.CrossRefPubMed Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70.CrossRefPubMed
8.
Zurück zum Zitat Fischell TA, Ebner A, Gallo S, Ikeno F, Minarsch L, Vega F, et al. Transcatheter alcohol-mediated perivascular renal denervation with the Peregrine system: first-in-human experience. JACC Cardiovasc Interv. 2016;9(6):589–98.CrossRefPubMed Fischell TA, Ebner A, Gallo S, Ikeno F, Minarsch L, Vega F, et al. Transcatheter alcohol-mediated perivascular renal denervation with the Peregrine system: first-in-human experience. JACC Cardiovasc Interv. 2016;9(6):589–98.CrossRefPubMed
9.
Zurück zum Zitat Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45.CrossRefPubMed Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45.CrossRefPubMed
10.
Zurück zum Zitat •• Jung O, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74. Important study which highlighted the substantial prevalence of drug-non-adherence in resistant hypertebnsion. CrossRefPubMed •• Jung O, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74. Important study which highlighted the substantial prevalence of drug-non-adherence in resistant hypertebnsion. CrossRefPubMed
11.
Zurück zum Zitat Florczak E, et al. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn. 2015;125(1–2):65–72.PubMed Florczak E, et al. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn. 2015;125(1–2):65–72.PubMed
12.
Zurück zum Zitat Patel P, Gupta PKC, White CMJ, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368–73.CrossRefPubMed Patel P, Gupta PKC, White CMJ, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368–73.CrossRefPubMed
13.
Zurück zum Zitat Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55.CrossRefPubMed Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55.CrossRefPubMed
14.
Zurück zum Zitat Flack JM, et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9:769–79.CrossRefPubMed Flack JM, et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9:769–79.CrossRefPubMed
15.
Zurück zum Zitat •• Mahfoud F, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the global SYMPLICITY registry. Eur Heart J. 2017;38(2):93–100. This registry will be an important source of long-term efficacy and saftery of renal denervation. PubMed •• Mahfoud F, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the global SYMPLICITY registry. Eur Heart J. 2017;38(2):93–100. This registry will be an important source of long-term efficacy and saftery of renal denervation. PubMed
16.
Zurück zum Zitat • Sata Y, et al. Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation. J Hypertens. 2018;36(6):1414–22. Given the difficulty predicting responses in RDN studies like this are going to become inreasingly important as subject selection is streamlined. CrossRefPubMed • Sata Y, et al. Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation. J Hypertens. 2018;36(6):1414–22. Given the difficulty predicting responses in RDN studies like this are going to become inreasingly important as subject selection is streamlined. CrossRefPubMed
17.
Zurück zum Zitat •• Osborn JW, Foss JD. Renal nerves and long-term control of arterial pressure. Compr Physiol. 2017;7(2):263–320. Well-written and comprehensive review or renal nerve anatomy and role in renal function. CrossRefPubMed •• Osborn JW, Foss JD. Renal nerves and long-term control of arterial pressure. Compr Physiol. 2017;7(2):263–320. Well-written and comprehensive review or renal nerve anatomy and role in renal function. CrossRefPubMed
19.
Zurück zum Zitat Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol. 2015;66(16):1766–75.CrossRefPubMed Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol. 2015;66(16):1766–75.CrossRefPubMed
20.
Zurück zum Zitat Fudim M, Sobotka AA, Yin YH, Wang JW, Levin H, Esler M, et al. Selective vs. global renal denervation: a case for less is more. Curr Hypertens Rep. 2018;20(5):37.CrossRefPubMed Fudim M, Sobotka AA, Yin YH, Wang JW, Levin H, Esler M, et al. Selective vs. global renal denervation: a case for less is more. Curr Hypertens Rep. 2018;20(5):37.CrossRefPubMed
21.
Zurück zum Zitat Tsioufis C, Dimitriadis K, Tsioufis P, Patras R, Papadoliopoulou M, Petropoulou Z, et al. ConfidenHT system for diagnostic mapping of renal nerves. Curr Hypertens Rep. 2018;20(6):49.CrossRefPubMed Tsioufis C, Dimitriadis K, Tsioufis P, Patras R, Papadoliopoulou M, Petropoulou Z, et al. ConfidenHT system for diagnostic mapping of renal nerves. Curr Hypertens Rep. 2018;20(6):49.CrossRefPubMed
22.
23.
Zurück zum Zitat Kopp UC. Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Integr Comp Physiol. 2015;308(2):R79–95.CrossRefPubMed Kopp UC. Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Integr Comp Physiol. 2015;308(2):R79–95.CrossRefPubMed
24.
Zurück zum Zitat Kopp UC, et al. Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1561–72.CrossRefPubMed Kopp UC, et al. Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1561–72.CrossRefPubMed
25.
Zurück zum Zitat Ueda H, Uchida Y, Kamisaka K. Mechanism of the reflex depressor effect by the kidney in dog. Jpn Heart J. 1967;8(6):597–606.CrossRefPubMed Ueda H, Uchida Y, Kamisaka K. Mechanism of the reflex depressor effect by the kidney in dog. Jpn Heart J. 1967;8(6):597–606.CrossRefPubMed
26.
Zurück zum Zitat Handa RK, Johns EJ. Interaction of the renin–angiotensin system and the renal nerves in the regulation of rat kidney function. J Physiol. 1985;369:311–21.CrossRefPubMedPubMedCentral Handa RK, Johns EJ. Interaction of the renin–angiotensin system and the renal nerves in the regulation of rat kidney function. J Physiol. 1985;369:311–21.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633–41.CrossRefPubMed DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633–41.CrossRefPubMed
28.
29.
Zurück zum Zitat Lambert T, Nahler A, Reiter C, Schwarz S, Gammer V, Blessberger H, et al. Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension. Am J Cardiol. 2015;115(11):1545–8.CrossRefPubMed Lambert T, Nahler A, Reiter C, Schwarz S, Gammer V, Blessberger H, et al. Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension. Am J Cardiol. 2015;115(11):1545–8.CrossRefPubMed
30.
Zurück zum Zitat •• Pappaccogli, M., et al., Effectiveness of renal denervation in resistant hypertension: a meta-analysis of 11 controlled studies. High Blood Press Cardiovasc Prev, 2018. https://doi.org/10.1007/s40292-018-0260-5. Accessed 11 May 2018. This analysis was published before more recent studies. It basically finds little benefit in RDN as done in the period up to about 2016 . CrossRef •• Pappaccogli, M., et al., Effectiveness of renal denervation in resistant hypertension: a meta-analysis of 11 controlled studies. High Blood Press Cardiovasc Prev, 2018. https://​doi.​org/​10.​1007/​s40292-018-0260-5. Accessed 11 May 2018. This analysis was published before more recent studies. It basically finds little benefit in RDN as done in the period up to about 2016 . CrossRef
Metadaten
Titel
Catheter-Based Renal Denervation for Hypertension
verfasst von
Raymond R. Townsend
Paul A. Sobotka
Publikationsdatum
01.11.2018
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 11/2018
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-018-0896-5

Weitere Artikel der Ausgabe 11/2018

Current Hypertension Reports 11/2018 Zur Ausgabe

Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Adipose Tissue and Modulation of Hypertension

Sleep and Hypertension (SJ Thomas, Section Editor)

Chronotherapy for Hypertension

Mechanisms of Hypertension (M Weir, Section Editor)

SPRINT and the Kidney: What Have We Learned?

Mechanisms of Hypertension (M Weir, Section Editor)

Modulation of Sympathetic Overactivity to Treat Resistant Hypertension

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

Skin Sodium and Hypertension: a Paradigm Shift?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.